Clinical trial
Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent
NCT01751763 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 9, 2013
- Completion date
- September 8, 2017
- Enrollment
- 106 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.